Spectral announces first quarter 2009 results
... 5,716 5,716 deficit ... Statements of Operations, Comprehensive Loss and deficit - unaudited For the three months ended March ... for the period (404) (448) deficit - Beginning of period ...Spectral announces 2008 financial results
... 5,716 5,606 deficit ... the year (1,502) (1,666) deficit - Beginning of year (2,687) ... ---------------------------- deficit - End of year (4,189) ...Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
... 511,866 502,163 Accumulated deficit (642,053) (576,501) Total stockholders' deficit (130,187) (74,338) Total liabilities and stockholders' deficit $263,002 $183,050 ...Spectral announces third quarter 2008 results
... 5,671 5,606 deficit ... Statements of Operations, Comprehensive Loss and deficit - unaudited For the nine months ended September ... (332) (382) (1,199) (968) deficit - Beginning of period ...Shire's New Product Portfolio Delivers Strong Quarterly Performance
... (lisdexamfetamine dimesylate) - Attention deficit and Hyperactivity Disorder ("ADHD") - The ... (lisdexamfetamine dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ... 85.6 55.7 Accumulated deficit (1,115.1) ...Monogram Announces 2008 Third Quarter Financial Results
... $69,311 LIABILITIES AND STOCKHOLDERS' deficit Current liabilities: Accounts payable ... - (31) Accumulated deficit (299,714) (287,539) Total stockholders' deficit (8,945) (1,240) ...Celebrity Designer Ty Pennington to Host 10th Annual 'ADHD Experts on Call' Program
... ADHD Experts to Answer Questions about Attention deficit Hyperactivity Disorder ... and caregivers of patients with Attention deficit Hyperactivity Disorder (ADHD), as well as adults ... M.D., director of the Adult Attention deficit Disorder Center of Maryland and assistant ...BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
... 1,261,211 Liabilities and Stockholders' deficit Current liabilities: Accounts payable and ... 1,092,925 4,751,447 Accumulated deficit (11,437,876) ... - (625,774) Total stockholders' deficit (1,387,399) (6,735,658) ...Kiwa Bio-Tech 2nd Quarter Revenues Increase 61.7% to $3 Million, Six Month Revenues Top $5.2 Million
... minority interest in a subsidiary's deficit (640,744) (893,134) (1,343,184) ... Minority interest in a subsidiary's deficit 9,723 750 25,968 ... reserve (224,764) (307,053) deficit accumulated (12,391,738) ...SemBioSys announces second quarter 2008 financial and operational results
... debenture 1,427,127 - deficit ... Statements of Loss, Comprehensive Loss and deficit (Unaudited) ... (3,225,371) (11,431,911) (6,453,782) deficit - Beginning of period (61,176,218) ...Bioheart, Inc. Announces Financial Results for Second Quarter 2008
... LIABILITIES AND SHAREHOLDERS' deficit Current liabilities Accounts payable ... Commitments and contingencies Shareholders' deficit Preferred stock ($0.001 par value) 5,000,000 ... 79,835,158 77,061,296 deficit accumulated during the development stage ...Galaxy Nutritional Foods Reports FY2008 Results
... $ 4,364,618 LIABILITIES AND STOCKHOLDERS' deficit CURRENT LIABILITIES: Secured borrowings ... 70,167,149 70,167,149 Accumulated deficit (70,970,948) (72,309,803) Total stockholders' deficit (632,699) (1,971,554) ...Advance Nanotech Reports First Quarter 2008 Financial Results
... 7,187,471 6,854,191 STOCKHOLDERS' deficit Preferred stock; $0.001 par value; 25,000,000 ... loss (1,372,437) (801,386) deficit accumulated during development stage ... (31,911,750) (30,826,109) TOTAL STOCKHOLDERS' deficit (15,829,177) (12,753,808) ...Bioheart, Inc. Announces Financial Results for First Quarter 2008
... LIABILITIES AND SHAREHOLDERS' deficit Current liabilities Accounts payable ... Commitments and contingencies Shareholders' deficit Preferred stock ($0.001 par value) ... 78,720,440 77,061,296 deficit accumulated during the development stage ...Vermillion Announces First Quarter 2008 Financial Results and Business Progress
... $24,053 Liabilities and Stockholders' deficit Current liabilities: Accounts payable ... 228,067 227,895 Accumulated deficit (243,988) ... (640) (221) Total stockholders' deficit (16,555) (11,462) ...Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
... screening initiative for adults with Attention deficit Hyperactivity Disorder (ADHD), a ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...SemBioSys announces first quarter 2008 financial and operational results
... 7,506,865 7,326,962 deficit (61,176,218) ... Statements of Loss, Comprehensive Loss and deficit (Unaudited) ... (5,017,055) (3,228,411) deficit - Beginning of period (56,159,163) ...Publication of Supplementary Prospectus
... Application for use in the treatment of Attention deficit Hyperactivity Disorder in adults, which was ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
... Product Highlights VYVANSE(TM) - Attention deficit and Hyperactivity Disorder ("ADHD") - By April ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... dimesylate) (Attention deficit and Hyperactivity Disorder ("ADHD")); the impact ...Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million
... Loss before minority interest in a subsidiary's deficit (2,893,027) (2,541,502) Minority interest in a subsidiary's deficit (332) ... reserve (307,053) (523,468) deficit accumulated (11,074,522) ...SemBioSys announces 2007 financial and operational results
... 7,326,962 5,475,404 deficit ... Statements of Loss, Comprehensive Loss and deficit For the years ended December 31, ... loss for the year (15,418,677) (14,127,086) deficit - Beginning of year ...NPS Pharmaceuticals Reports 2007 Financial Results
... (2,504) (1,892) Accumulated deficit (869,529) (868,872) Total stockholders' deficit (188,031) (193,244) Total liabilities and stockholders' deficit $231,757 $224,740 * Non-recourse debt ...Spectral announces 2007 financial results
... 5,606 5,489 deficit ... of Operations, Comprehensive (Loss) Income and deficit ... (1,666) 3,730 deficit - Beginning of period ...NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
... (500) (1,892) Accumulated deficit (890,734) (868,872) Net stockholders' deficit (209,698) (193,244) Total liabilities and stockholders' deficit $361,489 $224,740 About NPS ...SemBioSys announces 2007 third quarter results
... 6,026,443 5,475,404 deficit ... Statements of Loss, Comprehensive Loss and deficit (Unaudited) ... (2,659,025) (10,134,732) (9,771,546) deficit - Beginning of period (47,194,268) ...Shire Divests Non-Core Product Portfolio to Almirall
... Shire's focus is on building its attention deficit hyperactivity disorder (ADHD), human genetic ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... to the impact of those on Shire's Attention deficit and Hyperactivity Disorder (ADHD) franchise; ...Celebrity Designer Ty Pennington to Host 'ADHD Experts on Call' Program
... ADHD Experts to Answer Questions about Attention deficit Hyperactivity Disorder ... Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic ... to the impact of those on Shire's Attention deficit and Hyperactivity Disorder ("ADHD") franchise; ...WuXi PharmaTech Announces Second Quarter 2007 Results
... Liabilities, mezzanine equity and shareholders' deficit Current liabilities: Short-term bank ... (360) (360) Total shareholders' deficit (33,492) (928) ... mezzanine equity and shareholders' deficit 151,886 85,691 Note 1: Eight ...InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
... senior notes 130,471 155,084 Stockholders' deficit (80,642) (110,371) ... -------- Total liabilities and stockholders' deficit $165,647 $171,810 ...Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
... to assess the efficacy and safety of VYVANSE in non ADHD ("Attention deficit Hyperactivity Disorder") indications. Our HGT pipeline has been ... comprehensive income 119.7 97.0 Accumulated deficit (843.8) (1,051.7) Total Shire plc ...Vasogen Announces Second Quarter 2009 Results
... surplus 24,121 23,555 deficit (401,193) (397,857) ... STAGE COMPANY) Interim Consolidated Statements of Operations, deficit and Comprehensive Income (In thousands of Canadian dollars, except ...